Title: Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States

Authors: Kaitlin Rainwater-Lovett[1,2], John T. Redd[2], Miles A. Stewart[1,2], Natalia Elías Calles[3], Tyler Cuff[3], Mike Fang[1], Mark J. Panaggio[1], Anastasia S. Lambrou[1,2], Jonathan K. Thornhill[1,2], Christopher Bradburne[1,4], Samuel Imbriale[2], Jeffrey D. Freeman[1,2], Michael Anderson[2], Robert Kadlec[2]

Affiliations: [1]Asymmetric Operations Sector, Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland; [2]Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC; [3]Tucson Medical Center, TMC HealthCare, Tucson, Arizona; [4]McKusick-Nathans Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.

Keywords: Monoclonal antibody; bamlanivimab; SARS-CoV-2; COVID-19; emergency response

Running Title: Monoclonal Antibodies in COVID Patients

Corresponding Author: Kaitlin Rainwater-Lovett, PhD, MPH; Kaitlin.Lovett@jhuapl.edu

Alternate Corresponding Author: John T. Redd, MD, MPH; John.Redd@hhs.gov

Summary: In a diverse, real-world COVID-19 patient population, treatment with monoclonal antibodies significantly decreased the risk of subsequent emergency department visit or hospitalization within 30 days of a positive SARS-CoV-2 viral test.

ABSTRACT

Background: Monoclonal antibodies (mAbs) against SARS-CoV-2 are a promising treatment for limiting the progression of COVID-19 and decreasing strain on hospitals. Their use, however, remains limited, particularly in disadvantaged populations.

Methods: Electronic health records were reviewed from SARS-CoV-2 patients at a single medical center in the United States that initiated mAb infusions in January 2021 with the support of the U.S. Department of Health and Human Services' National Disaster Medical System. Patients who received mAbs were compared to untreated patients from the time period before mAb availability who met eligibility criteria for mAb treatment. We used logistic regression to measure the effect of mAb treatment on the risk of hospitalization or emergency department (E.D.) visit within 30 days of laboratory-confirmed COVID-19.

Results: Of 598 COVID-19 patients, 270 (45%) received bamlanivimab and 328 (55%) were untreated. Two hundred and thirty-one patients (39%) were Hispanic. Among treated patients, 5/270 (1.9%) presented to the E.D. or required hospitalization within 30 days of a positive SARS-CoV-2 test, compared to 39/328 (12%) untreated patients ($p<0.001$). After adjusting for age, gender, and comorbidities, the risk of E.D. visit or hospitalization was 82% lower in mAb-treated patients compared to untreated patients (95% confidence interval [CI]: 66%-94%).

Conclusions: In this diverse, real-world COVID-19 patient population, mAb treatment significantly decreased the risk of subsequent E.D. visit or hospitalization. Broader treatment with mAbs, including in disadvantaged patient populations, can decrease the burden on hospitals and should be facilitated in all populations in the United States to ensure health equity.

BACKGROUND

In late 2019, a new respiratory infection was detected in China and alarmed global health experts with its growing case incidence and clinical severity [1,2]. Over the course of a few months, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spread around the world, overwhelming health systems. While a substantial proportion of patients remain asymptomatic [3], coronavirus disease 2019 (COVID-19) can rapidly progress and require hospitalization and intensive care. Severe disease is associated with older age, obesity, and several chronic medical conditions including cardiovascular, kidney, and pulmonary comorbidities [4–7].

As of late January 2021, approximately 15,000 new COVID-19 hospital admissions were occurring per day in the United States (U.S.) and hospital bed capacity exceeded 72% [8,9]. As healthcare systems continued to approach maximum bed capacity, a critical need for therapeutic interventions to reduce COVID-related hospitalizations emerged. Although therapeutic options for COVID-19 remain limited, monoclonal antibodies (mAbs) that neutralize SARS-CoV-2 are a promising treatment for limiting the progression of disease. Four mAbs are available in the U.S. through Emergency Use Authorizations (EUAs) by the U.S. Food and Drug Administration (FDA): bamlanivimab monotherapy [10], bamlanivimab in combination with etesevimab [11], and casirivimab in combination with imdevimab [12]. These products are human IgG1 antibodies that neutralize the virus by binding the spike protein of SARS-CoV-2, preventing attachment of the virus to the human cellular receptor angiotensin-converting enzyme-2. A single infusion of bamlanivimab was recently demonstrated to reduce the risk of hospitalization, emergency department (E.D.) visits, and death among patients with mild to moderate COVID symptoms in randomized, controlled phase 2/3 trials by more than 70% [10].

Monoclonal antibodies are underutilized as a treatment for reducing severe disease and could significantly decrease hospitalizations and potentially long-term COVID effects [13]. Utilization can be particularly challenging in minority, disadvantaged populations, in whom prevalence of risk factors for COVID-19

progression and death may be higher [14]. Thus, mAb may be particularly underutilized in precisely the populations that would have the greatest benefit, threatening to exacerbate existing health inequities in the United States. Two primary barriers to implementation of mAb infusion therapy are: 1) a limited understanding of the necessary resources and processes to mobilize infusion sites, and 2) understanding the magnitude of the potential impact of mAb treatment on reducing the severity of disease. We previously addressed the first barrier through a process assessment and improvement analysis [15], demonstrating considerable flexibility in assembling an infusion site and the feasibility of mAb delivery in diverse treatment locations. Here, we aim to determine the extent to which mAb treatment decreases COVID-related hospital admission and E.D. visits among patients with mild to moderate COVID-19 within 30 days of treatment in the U.S..

METHODS

We conducted a retrospective cohort study in February 2021 of SARS-CoV-2-positive patients to evaluate the effect of mAb treatment on the risk of a medical visit within 30 days. This study evaluated patients who presented to a single medical center to which the U.S. Department of Health and Human Services' Assistant Secretary for Preparedness and Response (ASPR) had deployed elements of the National Disaster Medical System (NDMS) to establish a mAb infusion site. This medical center is located in a moderately sized city with a population of approximately 500,000. The city's population is 56.4% non-White with a median household income that is 64% of the U.S. level and a poverty rate of 23.4% [16,17]. This clinical support activity was conducted as part of the ASPR public health response to the COVID-19 pandemic and at the request of the host medical center. Under HHS Office of Health Research Protection guidelines, it was judged a non-research COVID-19 response [18]. The Johns Hopkins University Applied Physics Laboratory and the medical center concurred with a non-research determination.

101 The target population for this evaluation was patients with positive results of SARS-CoV-2 viral testing
102 who were 12 years of age or older, at least 40 kg in weight, and at high risk for progressing to severe
103 COVID-19 or hospitalization. Clinical data were obtained in February 2021 from electronic health
104 records maintained by the medical system, which includes both a major medical center and several
105 outpatient clinics with integrated health records.
106
107 Our retrospective cohort consisted of patients presenting to either outpatient clinics or the medical center
108 who tested positive for SARS-CoV-2 via an antigen or polymerase chain reaction-based test. Patients
109 with positive viral test results recorded in the electronic health record between July 1st and December 20th,
110 2020 were identified as untreated patients. These patients were eligible for inclusion in the analysis if they
111 met the eligibility criteria for mAb treatment (Table 1). Treatment with mAb became available at the
112 medical center on January 7th, 2021. SARS-CoV-2 patients who received mAb infusions between
113 January 7th and January 15th, 2021, are referred to as treated patients. We selected the test date of
114 December 20th, 2020, as the final date of eligibility for untreated patients to ensure no overlap in the
115 treated and untreated patient populations based on the maximum ten-day symptom onset window
116 permitting mAb treatment eligibility and decreased healthcare seeking behavior during winter holidays
117 [19]. The decision to seek mAb treatment for COVID-19 was made by the patient and the provider. At
118 presentation for mAb treatment, the date of SARS-CoV-2 test positivity was confirmed through paper
119 records provided by the patient or rapid antigen test performed on-site, and intake staff collected
120 demographic and clinical information, including eligibility criteria for treatment (Table 1). Any adverse
121 events were recorded on patient forms. While mAb treatments continued after January 15th, the end date
122 was established to permit sufficient follow-up at the time of data collection.
123
124 Data extracted from existing medical records included age, sex, race, ethnicity, height and weight, and
125 presence of the following pre-existing conditions as recorded by clinicians in the health record: blood
126 disorders (e.g., sickle cell disease, thalassemia), cancer, diabetes, Down syndrome, chronic lung disease,

127 chronic liver disease, hypertension, immunosuppressive condition, chronic kidney disease, obesity or
128 overweight, and organ transplant. Pre-existing conditions were captured from the Chief Complaint of
129 health records within the six months prior to the date of SARS-CoV-2 testing. Laboratory values and
130 clinical exam measurements were not extracted to define pre-existing conditions.
131
132 Race categories were defined as American Indian/Alaskan Native, Asian, Black, Hawaiian/Pacific
133 Islander, White, and other. Ethnicity was defined as Hispanic or Non-Hispanic. Body mass index (BMI)
134 was calculated as kilograms per meter-squared. In the absence of height and weight, the pre-existing
135 conditions of "obesity" and "overweight" were used for BMI categorization. The composite outcome of a
136 medical visit was defined as the first instance of COVID-19-related E.D. visit or hospitalization after
137 positive SARS-CoV-2 viral test result and was obtained from the electronic health record. A medical visit
138 was COVID-related if one or more of the following chief complaints were identified: blood in sputum,
139 chest congestion, chest pain, cough, COVID-19 screening, difficulty breathing, fever, flu-like symptoms,
140 hypoxia, shortness of breath, sore throat, or weakness [20–23]. Dates of COVID-19 symptom onset and
141 positive SARS-CoV-2 antigen test results performed at the infusion center were recorded on paper-based
142 forms upon arrival of patients for mAb treatment, but were not recorded in electronic health records.
143
144 Characteristics of patients were compared using Welch t-tests for continuous variables and Chi-squared
145 test for categorical variables. Age was categorized as younger than or equal to 65 years of age or older
146 than 65 years. Logistic regression was used to evaluate the effect of mAb treatment on medical visits that
147 occurred within 30 days of SARS-CoV-2-positive viral test by applying a generalized linear model with a
148 logits link function. The occurrence of a medical visit was evaluated as a binary outcome. Variables
149 included in the model were those deemed epidemiologically relevant. Model diagnostics indicated that no
150 data points substantially influenced model estimates, as assessed by Cook's distance. All data processing
151 and analyses were conducted using R version 4.0.3 [24].
152

153 **RESULTS**

154 Medical records were available from 875 SARS-CoV-2-positive patients (Figure 1) confirmed during July
155 1 through December 20, 2020. Of these, 547 patients did not meet eligibility criteria for mAb treatment
156 (Figure 1). This resulted in the analysis of 598 patients, 270 of whom (45%) were eligible for and
157 received bamlanivimab during a single week in January 2021, comprising the treated group. A total of
158 328 untreated patients (55%) served as the historical comparator population. These untreated patients
159 represented individuals who would have been eligible for mAb infusion had the treatment been available
160 at the time of their COVID-19-positive viral test results.

161

162 Among the 598 patients, no statistically significant differences in sex or ethnicity were identified between
163 the treated and untreated study groups (Table 2). Untreated patients were an average of three years
164 younger than the treated patients ($p=0.02$), and health records were more likely to report untreated
165 patients as overweight or obese and with a history of hypertension or cardiovascular disease (all $p<0.001$).

166

167 In the 30 days following a positive SARS-CoV-2 test result, five of 270 treated patients (1.9%) presented
168 to the E.D. or required hospitalization within 30 days of a positive SARS-CoV-2 test result, compared to
169 39 of the 328 untreated patients (12%) ($p<0.01$) (Table 2). Untreated patients had a medical visit a median
170 of four days after SARS-CoV-2-positive viral test result (interquartile range [IQR]: 2, 8 days), while
171 treated patients had a medical visit an average of eight days after mAb treatment (IQR: 4, 8) ($p=0.112$ by
172 Kolmogorov-Smirnov test). No adverse events were reported among mAb-infused patients.

173

174 Treatment with mAb was associated with an 82% decrease in the risk of a COVID-19-related medical
175 visit within 30 days of a positive SARS-CoV-2 viral test after adjusting for demographic factors and pre-
176 existing conditions (95% CI: 66%, 94%) (Table 3). A BMI ≥ 35 greatly increased the risk of a medical
177 visit in the multivariable analysis (odds ratio: 6.44 [95% CI: 2.48, 16.71]). Age ≥ 65 was also associated
178 with a 2.10-fold increased risk but this was not statistically significant (95% CI: 0.97, 4.77).

179

180 **DISCUSSION**

181 This study demonstrated that a single infusion of bamlanivimab within 10 days of COVID-19 symptom
182 onset decreased the risk of COVID-related hospitalization and E.D. visits among a real-world, diverse
183 patient population in the U.S. who were at risk of progression to severe disease compared with an
184 historical untreated population. The association between treatment and improved clinical outcome
185 remained significant after controlling for gender, age, race, ethnicity, and pre-existing conditions. A BMI
186 of greater than 35 remained highly associated with disease progression requiring a medical visit after
187 adjusting for mAb treatment and other co-factors.

188

189 Approximately 2% of the treated group were hospitalized or visited the E.D. after mAb infusion, which
190 was similar to the rate of medical visits in the efficacy assessment of bamlanivimab [10]. In contrast,
191 almost 12% of untreated patients in the current study required a medical visit within 30 days of a positive
192 COVID test. This risk was nearly double the 6.3% of placebo controls who presented to the E.D., required
193 hospitalization, or died in the Phase 2/3 trial [10], suggesting that the current study's patient population
194 was older and had a higher risk of progression to severe disease. This difference reinforces the need to
195 evaluate therapeutics in diverse populations and in real-world clinical situations, as patients who are
196 referred for and receive treatments often differ from those who are enrolled in a clinical trial.

197

198 Few treatment options have been available during the COVID-19 pandemic for reducing the severity of
199 disease and preventing hospitalization, leading to significant strain on many hospitals[8]. Reducing the
200 proportion of patients who progress to severe disease and require hospitalization by approximately 80%
201 would be of immense value to medical centers, in which intensive care units contain an average of only
202 15 staffed beds [25]. The availability of mAbs at no drug cost due to their procurement by the U.S.
203 government places a therapeutic option more easily within reach of many who are at the highest risk of
204 severe disease.

205

206 The use of electronic health records is a strength of the current study. Due to the medical center's
207 electronic record system, we were able to assemble a SARS-CoV-2-positive cohort who would have been
208 eligible for mAb treatment at the time of their diagnosis based on pre-existing risk factors, had the
209 therapeutics been available at that time. An additional strength of this study was the diverse patient
210 population in the area, resulting in the inclusion of a large proportion of patients of Hispanic ethnicity
211 (39%). Our results are consistent with prior clinical trial data showing a 70% reduction in medical visits
212 by mAb-infused patients compared to placebo controls[10]. A BMI of 35 or higher was a strong
213 independent predictor of an increased risk of medical visits, which was consistent with other COVID-19
214 studies [7].

215

216 A significantly larger proportion of untreated patients had co-morbidities that increase the risk of severe
217 COVID-19 outcomes compared to treated patients in the current study, notably a higher proportion with
218 elevated BMI. Although mAb treatment remained significantly associated with a decreased risk of
219 hospitalization or E.D. visit after adjusting for pre-existing conditions (82% reduction; 95% CI: 66%,
220 94%), the baseline differences between the treated and untreated groups suggest a potential difference in
221 accessibility of mAb treatment. For example, patients with fewer co-morbidities may have more easily
222 been able to avail themselves of treatment. The continued U.S. government efforts to increase access to
223 mAbs are intended to ensure that COVID-19 therapeutics are equally available to all patients - an
224 important national health equity consideration.

225

226 To receive mAb infusions, patients must seek out treatment within 10 days of a positive SARS-CoV-2
227 antigen test result. This can be burdensome and stresses the importance of widespread availability of
228 testing. Evidence also suggests that patients with more significant or severe co-morbidities are likely to
229 have more complete health records [26,27]. This effect may have overrepresented patients with more
230 severe chronic conditions into the untreated group based on the application of mAb eligibility criteria for

231 inclusion in the analysis. Additionally, without active follow-up of patient outcomes, misclassification of
232 the medical visit outcome was possible as patients could seek follow-up care at any facility. These
233 considerations and the differences between the study groups suggest confounders remain that were
234 unmeasured in this analysis. These limitations could be further evaluated in a larger, prospective,
235 observational study.
236
237 While individuals at increased risk of SARS-CoV-2 infection and severe disease are prioritized for
238 vaccination in most U.S. states, therapeutic options such as mAb infusions remain a necessity for those
239 who remain unvaccinated due to contraindications or vaccine hesitancy [28,29]. Although viral variants
240 are being discovered that are poorly neutralized by several mAbs in laboratory studies [30,31], suggesting
241 reduced effectiveness in patient populations, relatively minor adjustments to the currently available mAb
242 products can counter these changes. Additionally, the FDA has issued guidance encouraging use of
243 existing formulations, platforms, and clinical protocols to facilitate expedited review and rapid
244 introduction of these modified mAb products to general public [32].
245
246 In summary, we demonstrated that mAb treatment with bamlanivimab was associated with an
247 approximately 80% reduction in the risk of medical visits among a diverse COVID-19 patient population
248 under real-world conditions. Increasing availability and utilization of novel COVID-19 therapeutics may
249 improve patient outcomes, reduce burden on the health system, and contribute to increased health equity
250 in the United States.
251
252 **FUNDING AND CONFLICT OF INTEREST STATEMENT**
253 All authors have completed the ICMJE uniform disclosure form: all authors had financial support from
254 the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness
255 and Response for the submitted work; no financial relationships with any organizations that might have

256 an interest in the submitted work in the previous three years; no other relationships or activities that could
257 appear to have influenced the submitted work.
258

259 **ACKNOWLEDGEMENTS**
260 The authors acknowledge the significant efforts of George (Mark) Thorp, RN, EMT-P, who led and
261 coordinated the Disaster Medical Assistance Team's mAb infusion site set-up, initiation, and integration
262 with the Tucson Medical Center. The authors thank David W. Forest, Christopher Florko, and Judy
263 McCord from TMC Health Care, who provided extensive time and support for this analysis.
264

265 **REFERENCES**

266 1. ProMed-mail. Undiagnosed pneumonia - China (Hubei) Request for Information. 2019. Available
267 at: http://www.promedmail.org. Accessed 1 February 2021.

268 2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease
269 2019 (COVID-19) Outbreak in China. JAMA **2020**; 323:1239. Available at:
270 https://jamanetwork.com/journals/jama/fullarticle/2762130.

271 3. Yanes-Lane M, Winters N, Fregonese F, et al. Proportion of asymptomatic infection among
272 COVID-19 positive persons and their transmission potential: A systematic review and meta-
273 analysis. PLoS One **2020**; 15:e0241536. Available at:
274 https://dx.plos.org/10.1371/journal.pone.0241536.

275 4. Ou M, Zhu J, Ji P, et al. Risk factors of severe cases with COVID-19: a meta-analysis. Epidemiol
276 Infect **2020**; 148:e175. Available at:
277 https://www.cambridge.org/core/product/identifier/S095026882000179X/type/journal_article.

278 5. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019
279 (COVID-19) infection. Int Urol Nephrol **2020**; 52:1193–1194. Available at:
280 http://link.springer.com/10.1007/s11255-020-02451-9.

281 6. Oetjens MT, Luo JZ, Chang A, et al. Electronic health record analysis identifies kidney disease as
282 the leading risk factor for hospitalization in confirmed COVID-19 patients. PLoS One **2020**;
283 15:e0242182. Available at: https://dx.plos.org/10.1371/journal.pone.0242182.

284 7. Kompaniyets L, Goodman AB, Belay B, et al. Body Mass Index and Risk for COVID-19–Related
285 Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death —
286 United States, March–December 2020. MMWR Morb Mortal Wkly Rep **2021**; 70:355–361.
287 Available at: http://www.cdc.gov/mmwr/volumes/70/wr/mm7010e4.htm?s_cid=mm7010e4_w.

288 8. U.S. Interagency Data Strategy and Execution Working Group. Community Profile Reports. 2021.
289 Available at: https://beta.healthdata.gov/Health/COVID-19-Community-Profile-Report/gqxm-
290 d9w9. Accessed 14 March 2021.

291 9. U.S. Department of Health and Human Services. COVID-19 Reported Patient Impact and Hospital
292 Capacity by State Timeseries. 2021. Available at: https://healthdata.gov/Hospital/COVID-19-
293 Reported-Patient-Impact-and-Hospital-Capa/g62h-syeh. Accessed 1 February 2021.
294 10. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients
295 with Covid-19. N Engl J Med **2021**; 384:229–237. Available at:
296 http://www.nejm.org/doi/10.1056/NEJMoa2029849.
297 11. Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in Combination
298 With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19. JAMA **2021**;
299 325:632. Available at: https://jamanetwork.com/journals/jama/fullarticle/2775647.
300 12. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody
301 Cocktail, in Outpatients with Covid-19. N Engl J Med **2021**; 384:238–251. Available at:
302 http://www.nejm.org/doi/10.1056/NEJMoa2035002.
303 13. The National Academies of Sciences Engineering and Medicine. Rapid Expert Consultation on
304 Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics (January
305 29, 2021). Washington, D.C.: National Academies Press, 2021. Available at:
306 https://www.nap.edu/catalog/26063.
307 14. Lopez L, Hart LH, Katz MH. Racial and Ethnic Health Disparities Related to COVID-19. JAMA
308 **2021**; 325:719. Available at: https://jamanetwork.com/journals/jama/fullarticle/2775687.
309 15. Lambrou A, Stewart M, Rainwater-Lovett K, et al. Implementation of SARS-CoV-2 monoclonal
310 antibody infusion sites at three medical centers in the United States: Strengths and challenges to
311 inform COVID-19 pandemic and future public health emergency use. (Manuscript In Progress)
312 **2021**
313 16. Data USA. Tucson, AZ. 2018. Available at: https://datausa.io/profile/geo/tucson-az/. Accessed 21
314 March 2021.
315 17. U.S. Census Bureau. Income and Poverty in the United States: 2019. 2020. Available at:
316 https://www.census.gov/library/publications/2020/demo/p60-270.html.

317 18. U.S. Department of Health and Human Services. Research Guidance on Coronavirus. 2020.
318 Available at: https://www.hhs.gov/ohrp/regulations-and-policy/guidance/ohrp-guidance-on-covid-
319 19/index.html. Accessed 7 January 2021.
320 19. Ewing A, Lee EC, Viboud C, Bansal S. Contact, travel, and transmission: The impact of winter
321 holidays on influenza dynamics in the United States. J Infect Dis **2016**; :jiw642. Available at:
322 https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jiw642.
323 20. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict
324 potential COVID-19. Nat Med **2020**; 26:1037–1040. Available at:
325 http://www.nature.com/articles/s41591-020-0916-2.
326 21. Clifford CT, Pour TR, Freeman R, et al. Association between COVID-19 diagnosis and presenting
327 chief complaint from New York City triage data. Am J Emerg Med **2020**; Available at:
328 https://linkinghub.elsevier.com/retrieve/pii/S0735675720309864.
329 22. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in
330 primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev
331 **2020**; Available at: http://doi.wiley.com/10.1002/14651858.CD013665.
332 23. Perotte R, Sugalski G, Underwood JP, Ullo M. Characterizing COVID-19: A chief complaint
333 based approach. Am J Emerg Med **2020**; Available at:
334 https://linkinghub.elsevier.com/retrieve/pii/S0735675720308135.
335 24. R Core Team. R: A language and environment for statistical computing. 2017; Available at:
336 https://www.r-project.org/.
337 25. U.S. Department of Health and Human Services. Intensive Care Unit Bed Utilization by State.
338 2021. Available at: https://protect-public.hhs.gov/pages/hospital-utilization. Accessed 14 March
339 2021.
340 26. Wang EC-H, Wright A. Characterizing outpatient problem list completeness and duplications in
341 the electronic health record. J Am Med Informatics Assoc **2020**; 27:1190–1197. Available at:
342 https://academic.oup.com/jamia/article/27/8/1190/5867232.

343 27. Weiskopf NG, Rusanov A, Weng C. Sick patients have more data: the non-random completeness
344 of electronic health records. AMIA . Annu Symp proceedings AMIA Symp **2013**; 2013:1472–7.
345 Available at: http://www.ncbi.nlm.nih.gov/pubmed/24551421.
346 28. Kaiser Family Foundation. COVID-19 Vaccine Hesitancy: Trends, Reasons, and Subgroups. 2020.
347 Available at: https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-
348 december-2020/. Accessed 15 March 2021.
349 29. Nguyen KH, Srivastav A, Razzaghi H, et al. COVID-19 Vaccination Intent, Perceptions, and
350 Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination — United States,
351 September and December 2020. MMWR Morb Mortal Wkly Rep **2021**; 70:217–222. Available at:
352 http://www.cdc.gov/mmwr/volumes/70/wr/mm7006e3.htm?s_cid=mm7006e3_w.
353 30. Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and
354 B.1.1.7. Nature **2021**; Available at: http://www.nature.com/articles/s41586-021-03398-2.
355 31. Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by
356 monoclonal and serum-derived polyclonal antibodies. Nat Med **2021**; Available at:
357 http://www.nature.com/articles/s41591-021-01294-w.
358 32. US Department of Health and Human Services Food and Drug Administration Center for Drug
359 Evaluation and Research. Development of Monoclonal Antibody Products Targeting SARS-CoV-
360 2, Including Addressing the Impact of Emerging Variants, During the COVID-19 Public Health
361 Emergency: Guidance for Industry. 2021. Available at: https://www.fda.gov/regulatory-
362 information/search-fda-guidance-documents/development-monoclonal-antibody-products-
363 targeting-sars-cov-2-including-addressing-impact-emerging. Accessed 17 March 2021.
364 33. U.S. Centers for Disease Control and Prevention National Center for Health Statistics. Clinical
365 Growth Charts. 2017. Available at: https://www.cdc.gov/growthcharts/clinical_charts.htm.
366 Accessed 1 February 2021.
367

368 **FIGURES AND TABLES**

369 **Figure 1**. Flow diagram applying the inclusion criteria to collected health records that generated the final

370 study population.



371

372 **Table 1.** Eligibility criteria for SARS-CoV-2 monoclonal antibody infusions.

Inclusion Criteria	
Laboratory-confirmed COVID-19 (documented positive COVID-19 viral test result) Symptom onset within the last ten days ≥12 years of age and weight ≥40 kilograms Plus, at least ONE of the following risk factors:	

- Body mass index ≥ 35
- Chronic kidney disease
- Diabetes mellitus
- Immunosuppressive disease
- Currently receiving immunosuppressive treatment
- ≥ 65 years of age
- ≥ 55 years of age <u>AND</u>:
  o Cardiovascular disease, or
  o Hypertension, or
  o Chronic pulmonary obstructive disease/other chronic respiratory disease
	- 12 – 17 years of age <u>AND</u>:
	  o BMI ≥ 85th percentile for age and gender based on Centers for Disease Control and Prevention's growth charts[33], or
	  o Sickle cell disease, or
	  o Congenital or acquired heart disease, or
	  o Neurodevelopmental disorders (e.g., cerebral palsy), or
	  o A medically-related technological dependence (e.g., tracheostomy, gastrostomy, positive pressure ventilation unrelated to COVID-19), or
	  o Asthma, reactive airway, or other chronic respiratory disease that requires daily medication for control.

373

374 **Table 2.** Baseline demographic and medical characteristics of SARS-CoV-2-positive patients.

375 Abbreviations: Max, maximum; Min, minimum; SD, standard deviation.

	Untreated (N=328)	mAB Treated (N=270)	Overall (N=598)	P-value
Sex				0.10
Female	211 (64.3%)	155 (57.4%)	366 (61.2%)	
Male	117 (35.7%)	115 (42.6%)	232 (38.8%)	
Age				0.03
Mean (SD)	61.0 (17.8)	63.9 (15.9)	62.3 (17.0)	
Median [Min, Max]	65.0 [13.0, 98.0]	66.0 [18.0, 98.0]	65.0 [13.0, 98.0]	
Age greater than 65				0.33
Yes	168 (51.2%)	150 (55.6%)	318 (53.2%)	
No	160 (48.8%)	120 (44.4%)	280 (46.8%)	
Race				0.66
American Indian, Alaskan Native	5 (1.5%)	6 (2.2%)	11 (1.8%)	
Asian	5 (1.5%)	4 (1.5%)	9 (1.5%)	
Black	14 (4.3%)	5 (1.9%)	19 (3.2%)	
Hawaiian, Pacific Islander	1 (0.3%)	1 (0.4%)	2 (0.3%)	
Other	11 (3.4%)	6 (2.2%)	17 (2.8%)	
White	278 (84.8%)	214 (79.3%)	492 (82.3%)	
Missing	14 (4.3%)	34 (12.6%)	48 (8.0%)	
Ethnicity				0.58
Hispanic	129 (39.3%)	102 (37.8%)	231 (38.6%)	
Non-Hispanic	188 (57.3%)	133 (49.3%)	321 (53.7%)	
Missing	11 (3.4%)	35 (13.0%)	46 (7.7%)	
BMI				<0.01
30 or greater	52 (15.9%)	24 (8.9%)	76 (12.7%)	
35 or greater	35 (10.7%)	11 (4.1%)	46 (7.7%)	
Hypertension				<0.01
Yes	176 (53.7%)	55 (20.4%)	231 (38.6%)	
No	152 (46.3%)	215 (79.6%)	367 (61.4%)	
Chronic Kidney Disease				0.22
Yes	19 (5.8%)	9 (3.3%)	28 (4.7%)	
No	309 (94.2%)	261 (96.7%)	570 (95.3%)	
Cardiovascular Disease				<0.01
Yes	71 (21.6%)	20 (7.4%)	91 (15.2%)	
No	257 (78.4%)	250 (92.6%)	507 (84.8%)	
Admission				<0.01
Yes	39 (11.9%)	5 (1.9%)	44 (7.4%)	
No	289 (88.1%)	265 (98.1%)	554 (92.6%)	

376

377 **Table 3.** Risk of COVID-19-related hospitalization or emergency department visit within 30 days of

378 SARS-CoV-2-positive viral test. *p<0.05. Abbreviations: CI, confidence interval; mAb, monoclonal

379 antibody; OR, odds ratio.

	Unadjusted		**Adjusted**	
	OR	[95% CI]	OR	[95% CI]
(Intercept)			0.05	[0.02, 0.12]
Gender				
Female	1.00	[0.54, 1.93]	0.88	[0.44, 1.78]
Male	*Reference*		*Reference*	
Age (years)				
≤64	*Reference*		*Reference*	
>65	1.06	[0.57, 1.99]	2.10	[0.97, 4.77]
Race				
Black	1.60	[0.23, 5.90]	1.2	[0.17, 5.12]
White	*Reference*		*Reference*	
Other	0.36	[0.02, 1.71]	0.35	[0.02, 1.79]
Unknown	0.29	[0.01, 1.35]	0.54	[0.03, 2.87]
Ethnicity				
Hispanic	1.50	[0.80, 2.78]	1.66	[0.84, 3.32]
Non-Hispanic	*Reference*		*Reference*	
Body Mass Index				
<30	*Reference*		*Reference*	
≥30 and <35	1.61	[0.67, 3.46]	1.98	[0.76, 4.76]
≥35	4.95	[2.21, 10.5]*	6.44	[2.48, 16.71]*
Comorbidities				
Hypertension	2.22	[1.19, 4.19]*	1.37	[0.67, 2.81]
Chronic Kidney Disease	1.61	[0.36, 4.89]	1.15	[0.25, 3.79]
Cardiovascular Disease	1.73	[0.78, 3.54]	1.07	[0.45, 2.40]
mAb Treatment	0.14	[0.05, 0.34]*	0.18	[0.06, 0.44]*

380

381 **Supplemental Table.** STROBE Statement

	Item No	Recommendation	Page No
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract, (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Pg 3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Pgs 4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	Pg 5
Methods			
Study design	4	Present key elements of study design early in the paper	Pgs 5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pgs 5-6
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (*b*) For matched studies, give matching criteria and number of exposed and unexposed	Pg 6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Pgs 6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pgs 6-7
Bias	9	Describe any efforts to address potential sources of bias	Pg 6
Study size	10	Explain how the study size was arrived at	Pgs 6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Pgs 7-8
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding (*b*) Describe any methods used to examine subgroups and interactions (*c*) Explain how missing data were addressed (*d*) If applicable, explain how loss to follow-up was addressed (*e*) Describe any sensitivity analyses	Pg 8
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	Pg 8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	Pg 8
Outcome data	15*	Report numbers of outcome events or summary measures over time	Pg 9

Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (*b*) Report category boundaries when continuous variables were categorized (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Pg 9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	Pgs 9-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pg 11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Pg 12
Generalisability	21	Discuss the generalisability (external validity) of the study results	Pgs 9, 12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Pg 12

382